Respiratory syncytial virus and palivizumab: Where are we in 2014?

被引：0

作者：

Robinson, Joan ^{[1
]}

机构：

[1] Univ Alberta, Edmonton, AB T6G 1C9, Canada

来源：

CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY | 2014年 / 25卷 / 01期

关键词：

HUMANIZED MONOCLONAL-ANTIBODY; PREMATURE-INFANTS; HOSPITALIZATION; PROPHYLAXIS; IMMUNOPROPHYLAXIS;

D O I：

10.1155/2014/158919

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：11 / 12

页数：2

共 19 条

[1]

Banerji A, 2013, INT J CIRCUMPOL HEAL, V72

[2] Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants [J].

Banerji, Anna ;

Lanctot, Krista L. ;

Paes, Bosco A. ;

Masoud, Shababa T. ;

Tam, Derrick Y. ;

Macdonald, W. Alexander ;

Roberts, Ann .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (08) :702-706

[3] Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants [J].

Blanken, Maarten O. ;

Rovers, Maroeska M. ;

Molenaar, Jorine M. ;

Winkler-Seinstra, Pauline L. ;

Meijer, Adam ;

Kimpen, Jan L. L. ;

Bont, Louis .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (19) :1791-1799

[4] POTENTIAL FOR PALIVIZUMAB INTERFERENCE WITH COMMERCIALLY AVAILABLE ANTIBODY-ANTIGEN BASED RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC ASSAYS [J].

Deming, Damon J. ;

Patel, Nita ;

McCarthy, Michael P. ;

Mishra, Lalji ;

Shapiro, Alan M. ;

Suzich, JoAnn A. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (10) :1144-1146

[5] Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease [J].

Feltes, TF ;

Cabalka, AK ;

Meissner, C ;

Piazza, FM ;

Carlin, DA ;

Top, FH ;

Connor, EM ;

Sondheimer, HM .

JOURNAL OF PEDIATRICS, 2003, 143 (04) :532-540

[6] Treatment of respiratory syncytial virus with palivizumab: a systematic review [J].

Hu, Jia ;

Robinson, Joan L. .

WORLD JOURNAL OF PEDIATRICS, 2010, 6 (04) :296-300

[7] Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus [J].

Johnson, S ;

Oliver, C ;

Prince, GA ;

Hemming, VG ;

Pfarr, DS ;

Wang, SC ;

Dormitzer, M ;

OGrady, J ;

Koenig, S ;

Tamura, JK ;

Woods, R ;

Bansal, G ;

Couchenour, D ;

Tsao, E ;

Hall, WC ;

Young, JF .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (05) :1215-1224

[8] RSV Immunoprophylaxis: Does the Benefit Justify the Cost? [J].

Meissner, H. Cody ;

Kimberlin, David W. .

PEDIATRICS, 2013, 132 (05) :915-918

[9]

National Advisory Committee on Immunization, 2003, CANADA COMMUNICABLE, P29

[10]

Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531

← 1 2 →